through 5 year follow-up, a range of 33% through 46% of UI subjects achieved complete urinary continence at different follow-up visits. At 5 years, 45% of UI subjects achieved complete urinary continence. For all implanted subjects the most common device-related AEs were undesirable change in stimulation (60/272, 22%), implant site pain (40/272, 15%), and therapeutic product ineffective (36/272, 13%).
INTRODUCTION AND OBJECTIVES: Nocturia (waking at night to void) is a bothersome condition associated with many underlying etiologies. Two randomized, placebo-controlled phase 3 trials demonstrated the efficacy/safety of SER120, a very low-dose desmopressin nasal spray formulation in patients (pts) with nocturia. A pooled analysis of the two trials compared the efficacy of SER120 in nocturia pts with contributing etiologies of nocturnal polyuria (NP), overactive bladder (OAB), and benign prostatic hyperplasia (BPH).
METHODS: Two phase 3 trials enrolled pts 50 y of age with 2 nocturic episodes/night (irrespective of etiology) for at least 6 months. Pts (N¼1333) were randomized 1:1:1 to SER120 0.75 mcg, 1.5 mcg or placebo for a 12-week treatment period after a 2-week doubleblind, placebo lead-in phase. Data from the two phase 3 trials were pooled for analysis by the contributing etiologies of NP (n¼1045); OAB (n¼366); and BPH (n¼518). The co-primary efficacy endpoints were mean change from baseline in nocturic episodes/night and percentages of pts with 50% reduction in mean nocturic episodes/night. RESULTS: Overall, the baseline mean nocturic episodes/night were 3.3, 3.4 and 3.3 in the SER120 0.75 mcg, 1.5 mcg, and placebo groups, respectively. SER120 at both doses resulted in significantly greater reductions in nocturic episodes/night vs placebo, regardless of etiology. The mean reductions in nocturic episodes with SER120 0.75 and 1.5 mcg vs placebo were -1.4 and -1.5 vs -1.2 in pts with NP (P<.0001 for both doses); -1.4 and -1.5 vs -1.0 in OAB pts (P¼.0015; P<.0001 ); and -1.3 and -1.4 vs -1.1 in BPH pts (P¼.0236; P¼.0063). A significantly higher percentage of pts achieved 50% reduction in nocturic episodes/night in groups with NP (37.3% and 48.0% vs 27.5%; P¼.0055; P<.0001), OAB (40.2% and 48.9% vs 28.3%; P¼.0452; P¼.0005) and BPH (31.4% and 38.3% vs 22.5%; P¼.0012 for 1.5 mcg).
CONCLUSIONS: SER120 at doses of 0.75 mcg and 1.5 mcg is effective for the treatment of nocturia in pts with any etiology or a combination of etiologies, including those diagnosed with NP, OAB and BPH. Pts experienced significantly greater reductions in mean nocturic episodes with SER120 at both doses, regardless of etiology. Significantly higher responder rates were achieved with SER120 at both doses in pts with NP and OAB, and with SER120 1.5 mcg dose in pts with BPH. SER120 had an adequate safety profile and was well tolerated.
Source of Funding: Allergan plc, Serenity Pharma LLC.
PD26-04 MEDIUM TERM OUTCOMES OF VENTRAL-ONLAY BUCCAL MUCOSA GRAFT SUBSTITUTION URETHROPLASTY FOR URETHRAL STRICTURE IN FEMALES
Bashir Mukhtar*, Marco Spilotros, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, London, United Kingdom INTRODUCTION AND OBJECTIVES: Female urethral stricture causes significant morbidity. There is a high rate of recurrence following endoscopic management. Urethroplasty for female urethral stricture (FUS) is a rare but increasingly common procedure. We report our medium term outcomes for ventral-onlay buccal mucosa graft substitution urethroplasty (VOBMGSU) in treating FUS.
METHODS: From our prospectively acquired database we reviewed the outcomes of 22 consecutive women (median age 50 years, range 34-72) with FUS having VOBMGSU from June 2012 and with a minimum follow up of 6 months (median 21.5, range 6-51). Data was analysed for complications, stricture recurrence, change in median peak free flow rate (Qmax) and median post-void residuals (PVR). Statistical analysis was performed using the Wilcoxon signed rank test, Students TTest and Mann-Whitney U Test .
RESULTS: At last follow-up 21/22 (95%) of women were stricture free. Median Qmax was significantly improved from 7 ml/s (range 3.5-11.2) to 18 ml/s (range 5-37) (p < 0.05). Median PVR was significantly reduced from 100mls (range 0-300) to 15 mls (range 0-150) (p < 0.05). Short and longer-term complication rates were low. 1 patient developed mild de novo stress urinary incontinence, which settled with conservative measures by 6 months.
CONCLUSIONS: Early and medium term results indicate that VOBMGSU is an excellent treatment for female urethral stricture that can avoid the need for the repeat procedures regularly required after traditional endoscopic management. Several studies demonstrated the association between LUTS and atherosclerosis risk factors and metabolic syndrome. However, a direct impact of chronic pelvic ischemia on LUTS in elderly men was never fully determined. The only evidence is coming from animal models of iliac obstruction which show significant bladder dysfunction after ischemia. Herewith, we investigated LUTS and urinary levels of nerve growth factor (NGF) in elderly men with chronic pelvic ischemia caused by documented aorta, unilateral or bilateral common/internal iliac obstruction.
METHODS: Thirteen men >60y, with aorta, unilateral or bilateral common/internal iliac artery occlusion documented by angio-CT Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e507
